All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Effect of Anti-Programmed Cell Death Protein-1 Antibody Combined with Paclitaxel on Cervical Cancer via Phosphoinositide 3-Kinase/Protein Kinase B Pathway in Rats

Author(s): Chong Shi*, G. Zhang, Liyan Peng and K. Zhang
Department of Prenatal Diagnosis and Genetic Diagnosis Center, Tangshan Maternal and Child Health Care Hospital, 1Department of Graduate, North China University of Science and Technology, 2Department of Pharmacy Tangshan Maternal and Child Health Care Hospital, Tangshan, Hebei 063000, 3Ren Sheng Zhong Chuang Marketing Consultant (Shanghai) Co., Ltd., Shanghai 200435, P. R. China

Correspondence Address:
Chong Shi, Department of Prenatal Diagnosis and Genetic Diagnosis Center, Tangshan Maternal and Child Health Care Hospital, Shanghai 200435, P. R. China, E-mail: [email protected]


The therapeutic effect of combined drugs on cervical cancer has been confirmed. Whether antiprogrammed cell death protein 1 antibody combined with paclitaxel mediates the phosphoinositide 3-kinase-protein kinase B pathway to regulate cervical cancer still needs further research. 20 nude mice received subcutaneous administration of Henrietta Lacks cells to establish cervical cancer model which was then assigned into blank control group, control group A (programmed cell death protein 1 antibody (5 mg/ kg) administration), control group B (paclitaxel) and observation group (programmed cell death protein 1 antibody combined with paclitaxel) followed by analysis of cell proliferation, apoptosis, expression of phosphoinositide 3-kinase-protein kinase B signaling related proteins and messenger ribonucleic acids. Observation group had lowest tumor size, highest cell proliferation inhibition rate and cell apoptosis, which were all reversed in blank group with largest tumor size, lowest cell proliferation inhibition rate and cell apoptosis. There was no difference between control group A and control group B (p>0.05). The expressions of phosphoinositide 3-kinase, protein kinase B, tumor protein p53 and tumor protein p21 were lowest in observation group and highest in blank group. In addition, control group had no significant difference with control group B (p>0.05). Anti-programmed cell death protein 1 antibody combined with paclitaxel may inhibit the activity of phosphoinositide 3-kinase-protein kinase B signaling, thereby downregulating phosphoinositide 3-kinase, protein kinase B, tumor protein p53 and tumor protein p21, controlling cervical cancer cell division, promoting cell apoptosis and finally exerting anti-tumor effects.

Full-Text | PDF

 
 
List of Supporting Conferences